BioCryst Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Good afternoon, everybody. Thanks for joining us. Jon Wolleben, senior analyst at JMP. We're pleased to have BioCryst Pharmaceuticals with us today, CEO, Jon Stonehouse, and Chief Development Officer and Chief R&D Officer, Helen Thackray. So, thanks, guys.
Questions & Answers
We're going to really touch on a little bit everything today. So I think what most people ask me about and probably ask you about is ORLADEYO to start, and maybe if you can give us an update, we just had the first quarter numbers, you reiterated your guidance for at least $220 million in sales. Tell us, how the early year progress and how things are tracking so for.
Sure. Thanks, Jon, for having us here. I don't know if I thought I'd say this, but good to be back in New York again, and to be in person. Helen and I are going to be making some forward-looking statements and those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
